XML 38 R25.htm IDEA: XBRL DOCUMENT v3.24.4
SEGMENT INFORMATION (Tables)
12 Months Ended
Oct. 31, 2024
Segment Reporting [Abstract]  
SCHEDULE OF SEGMENT INFORMATION

   2024   2023 
   Year Ended October 31, 
   2024   2023 
Net loss:          
Cancer Vaccines  $(7,388)  $(5,111)
CAR-T Therapeutics   (5,256)  $(3,879)
Other   (54)   (940)
Total  $(12,698)  $(9,930)
           
Total operating costs and expenses  $13,831   $11,221 
Less non-cash stock-based compensation   (4,782)   (4,735)
Operating costs and expenses excluding non-cash stock-based compensation  $9,049   $6,486 
           
Operating costs and expenses excluding non-cash stock-based compensation:          
Cancer Vaccines  $5,235   $3,265 
CAR-T Therapeutics   3,766    2,467 
Other   48    754 
Total  $9,049   $6,486 

 

   2024   2023 
   October 31, 
   2024   2023 
Total assets:          
Cancer Vaccines  $12,917   $17,215 
CAR-T Therapeutics   8,535    7,523 
Other   139    784 
Total  $21,591   $25,522